Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
Background/Aims Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that i...
| Autori principali: | , , , |
|---|---|
| Natura: | Articolo |
| Lingua: | English |
| Pubblicazione: |
Korean Association for the Study of Intestinal Diseases
2022-01-01
|
| Serie: | Intestinal Research |
| Soggetti: | |
| Accesso online: | http://irjournal.org/upload/pdf/ir-2020-00117.pdf |